Common Contracts
7 similar Underwriting Agreement contracts by Pacific City Financial Corp, Sientra, Inc., Anterios Inc, others
Precision BioSciences, Inc. 2,500,000 Shares of Common Stock, par value $0.000005 per share and Warrants to Purchase 2,500,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • March 1st, 2024 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • New York
Precision BioSciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Guggenheim Securities LLC (the “Underwriter”) an aggregate of (i) 2,500,000 shares of common stock, par value $0.000005 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and (ii) warrants to purchase up to 2,500,000 shares of Common Stock in the form set forth in Exhibit A hereto (the “Underwritten Warrants” and, together with the Underwritten Shares, the “Underwritten Securities”). In addition, at the option of the Underwriter, up to (i) 375,000 additional shares of Common Stock (the “Option Shares” and, collectively with the Underwritten Shares, the “Shares”) and (ii) additional Warrants to purchase an aggregate of 375,000 of Common Stock (the “Option Warrants” and, collectively with the Underwritten Warrants, the “Warrants”). The Underwritten Securities, and if and to the extent such option is exercised, the Option Shares, including the Warrant Shares (as defined b
5,410,628 Shares SIENTRA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2021 • Sientra, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
Sientra, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of 5,410,628 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”). The Company also proposes to sell to the Underwriters, at the option of the Underwriters, up to an additional 811,594 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”. To the extent there are no additional Underwriters listed on Schedule I other than the Representative, the term Representative as used herein shall mean you, as Underwriters, and the term Underwriter shall mean either the singular or plural as the context requires
17,391,305 Shares SIENTRA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 5th, 2019 • Sientra, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
Sientra, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 17,391,305 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, up to an additional 2,608,695 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
2,385,000 Shares PACIFIC CITY FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2018 • Pacific City Financial Corp • State commercial banks • New York
] Shares PACIFIC CITY FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2018 • Pacific City Financial Corp • State commercial banks • New York
] Shares ANTERIOS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 27th, 2015 • Anterios Inc • Pharmaceutical preparations • New York
or other arrangement, without, in each case, the prior written consent of the Representatives, which consent may be withheld in the Representatives’ sole discretion.
Common Stock JAGUAR ANIMAL HEALTH, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 28th, 2014 • Jaguar Animal Health, Inc. • Pharmaceutical preparations • New York
Jaguar Animal Health, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [·] shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional [·] shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. BMO Capital Markets Corp. and Guggenheim Securities, LLC are acting as representatives (the “Representatives”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
